Elinzanetant Patent Expiration
Elinzanetant was first introduced by Bayer Healthcare Pharmaceuticals Inc
Elinzanetant Patents
Given below is the list of patents protecting Elinzanetant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lynkuet | US12533358 | May 14, 2045 | Bayer Hlthcare | |
| Lynkuet | US10774091 | Soft Gelatin Capsule Formulation | Mar 13, 2039 | Bayer Hlthcare |
| Lynkuet | US11787820 | Method Of Treating Certain Sex Hormone-Dependent Diseases Administering A Soft Gelatin Capsule Comprising Nk1 And Nk3 Receptors Antagonists | Mar 13, 2039 | Bayer Hlthcare |
| Lynkuet | US12264164 | Method Of Treatment Of Symptoms Of Menopause | Mar 13, 2039 | Bayer Hlthcare |
| Lynkuet | US10195205 | Uses Of Dual Nk1/Nk3 Receptor Antagonists For Treating Sex-Hormone Diseases | May 18, 2036 | Bayer Hlthcare |
| Lynkuet | US7683056 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | Sep 15, 2027 | Bayer Hlthcare |
Elinzanetant's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Elinzanetant:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants | Bayer | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer | Bayer | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Finding Links Between Hot flASHes and CardioVascular Disease | Massachusetts General Hospital | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |